RBC Capital Markets raised its price target on BioMarin Pharmaceuticals (BMRN) Wednesday after a meeting with management raised hope for approval of its muscular-dystrophy drug. Analyst Michael Yee lifted his target on BioMarin stock to 155 from 145, assigning a 65% probability of approval to drisapersen, the Duchenne muscular dystrophy (DMD) drug that is due for an FDA decision by Dec. 27. Among his reasons for confidence: “totality of three
With quarterly earnings queuing up to be announced and the stock market under pressure, it’s a good time to look over top-rated companies such as Palo Alto Networks (PANW) and Ambarella (AMBA) that are expected to show strong profit growth. Today’s Screen Of The Day is Young Guns, top-rated companies that have gone public in the last 15 years. A second sort culls the five companies on the list that are estimated to have had the biggest earnings
Comcast’s stock buyback plans are a hot topic on Wall Street amid the arrival of a new chief financial officer. Comcast (CMCSA) is slated to report Q2 earnings on July 23. Stock repurchase plans — along with questions over M&A strategy, international growth and the performance of NBCUniversal — will likely highlight Comcast’s earnings call with analysts. Comcast stock has edged up 6% to record highs since April 24, when the No. 1 cable firm